How does AstraZeneca's international diversification compare to Pfizer's revenue base?

AstraZeneca maintains significant revenue diversification across developed and emerging markets internationally, which has supported steadier recent growth, while Pfizer's revenue base has been more affected by the sharp decline in pandemic-related product sales that were concentrated in specific vaccine and treatment categories, creating a larger recovery gap for Pfizer to close.

What metrics matter most when comparing PFE and AZN?

For Pfizer, watch post-pandemic revenue recovery progress and oncology pipeline growth following recent acquisitions. For AstraZeneca, focus on oncology pipeline growth and international market expansion, along with rare disease segment growth trends.

Why has AstraZeneca's growth been steadier than Pfizer's in recent years?

AstraZeneca's growth has been driven primarily by its ongoing oncology franchise expansion and rare disease segment growth, both of which have grown organically without the dramatic swing that Pfizer experienced from a large, temporary surge in pandemic-related vaccine and treatment revenue followed by a subsequent sharp decline as that demand normalized.

How is the AI score calculated?

The AI score is a composite signal incorporating fundamental quality, valuation, momentum, analyst sentiment, and risk factors. A higher score indicates a more favorable overall setup relative to the market at the time of the latest update.

Data as of: August 23, 2026

brimindinvest.com / compare / pfe-vs-aznLIVE

PFE

Pfizer Inc. · Healthcare

N/A

N/A this month

VERSUS

COMPARE

AZN

AstraZeneca PLC · Healthcare

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

PFE N/A

AZN N/A

1Y Returni

PFE N/A

AZN N/A

Fwd P/Ei

PFE N/A

AZN N/A

Target Up.i

PFE N/A

AZN N/A

Op. Margini

PFE N/A

AZN N/A

Quick take

PFE vs AZN Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

Pfizer and AstraZeneca are both major global pharmaceutical companies, but Pfizer is working to rebuild revenue growth following the decline of pandemic-related product sales, while AstraZeneca has maintained more consistent recent growth driven by its oncology franchise, rare disease segment, and diversified international revenue base.

Pfizer offers a potential recovery and pipeline rebuilding story following its pandemic-era revenue decline, while AstraZeneca offers exposure to a more consistently growing, internationally diversified pharmaceutical business. Consider whether you prefer Pfizer's recovery potential or AstraZeneca's steadier recent growth trajectory.

Want a full valuation workup? 46-section report — AI Score, Monte Carlo forecast, bull/bear case, DCF, and more.

PFE Report

Normalized 1Y performance

PFE

AZN

Not enough data to chart yet.

Recent returns

PFE

AZN

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

PFE

Price target data unavailable

N/A

AZN

Price target data unavailable

N/A

Who should consider this stock?

PFE may suit investors who:

Believe pipeline execution and recent oncology acquisitions can rebuild revenue growth
Are comfortable with dividend sustainability questions tied to post-pandemic revenue decline
See potential in Pfizer's mRNA technology platform applications beyond vaccines
Want to bet on a turnaround story within a large, well-established pharmaceutical company

AZN may suit investors who:

Want exposure to a more consistently growing global pharmaceutical business
Value diversification from a strong oncology franchise alongside a growing rare disease segment
Believe international revenue diversification, including emerging markets, supports long-term growth
Prefer a currently steadier growth trajectory over a company still rebuilding from a revenue decline

Performance & AI score

Performance & AI score
Metric	PFE	AZN
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	PFE	AZN
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Full DCF model for PFE

Growth, profitability & risk

Growth, profitability & risk
Metric	PFE	AZN
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

PFE max drawdowniN/A

AZN max drawdowniN/A

PFE max wkly dropiN/A

AZN max wkly dropiN/A

5Y risk snapshot

PFE max drawdowniN/A

AZN max drawdowniN/A

PFE max wkly dropiN/A

AZN max wkly dropiN/A

10Y risk snapshot

PFE max drawdowniN/A

AZN max drawdowniN/A

PFE max wkly dropiN/A

AZN max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	PFE	AZN
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

PFE

+2.8%BUY

AZN

+1.1%HOLD

Next 30 trading days

PFE

+6.4%BUY

AZN

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	PFE	AZN
Company	Pfizer Inc.	AstraZeneca PLC
Sector	Healthcare	Healthcare
Industry	N/A	N/A
Core business	A global pharmaceutical company with a broad portfolio spanning vaccines, oncology, and other therapeutic areas, working to rebuild revenue growth and pipeline momentum following the decline of pandemic-related product sales.	A UK-based global biopharmaceutical company with a strong oncology franchise alongside growing rare disease and biopharmaceuticals segments, maintaining significant international revenue diversification across developed and emerging markets.
Investor focus	Post-pandemic revenue recovery progress, oncology pipeline growth following recent acquisitions, and dividend sustainability given the revenue decline from prior pandemic-era products.	Oncology pipeline growth and international market expansion, rare disease segment growth trends, and overall pipeline productivity relative to global pharmaceutical peers.

PFE strengths

Broad pharmaceutical portfolio spanning vaccines, oncology, and other therapeutic areas provides multiple avenues for revenue diversification
Recent oncology-focused acquisitions have expanded the pipeline and provide potential new sources of long-term growth
mRNA technology platform experience gained through pandemic vaccine development offers potential applications in future therapies

AZN strengths

Strong oncology franchise combined with a growing rare disease segment provides diversified sources of pharmaceutical growth
Significant international revenue diversification, including meaningful presence in emerging markets, reduces dependence on any single geography
Consistent track record of pipeline productivity has supported steady revenue growth in recent years

Risks to watch — PFE

Revenue has declined significantly from peak pandemic-related product sales, requiring successful pipeline execution to rebuild growth
Dividend sustainability depends on successfully offsetting lost pandemic-era revenue with new product growth
Faces ongoing patent expirations across its broader pharmaceutical portfolio that require pipeline replenishment

Risks to watch — AZN

Faces ongoing patent expirations across its portfolio that require sustained pipeline innovation to offset
International revenue exposure introduces currency translation risk across its diverse geographic footprint
Emerging market revenue can carry additional regulatory, pricing, and economic volatility risk

Frequently asked questions

PFE offers a potential recovery and pipeline rebuilding story following its pandemic-era revenue decline, while AZN offers exposure to a more consistently growing, internationally diversified pharmaceutical business. The better choice depends on whether you prefer Pfizer's recovery potential or AstraZeneca's steadier growth trajectory.

Interactive comparison engine

Compare more than two at a time

This page is a fixed writeup on PFE and AZN. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.

Up to 5 tickers at once

Add three more names beside PFE and AZN, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.

Scoreboard verdict

AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.

Full risk suite

Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.

Correlation heatmap

Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.

Valuation vs profitability

A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.

Holdings overlap and CSV export

For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.

Open PFE vs AZN in the engine See what's included

Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

In-Depth Reports

Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.

PFE Report

Related comparisons